Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CCNH | P51946 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7845276 | 0.87 | BRD4 (0.48) | BRD4MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7836822 | 0.87 | CDK7 (0.44) | BRD4CCNT1CDK7CDK9CCNH | |
| SCHEMBL7847402 | 0.84 | MEN1 (0.49) | BRD4MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8391492 | 0.83 | SMN1; SMN2 (0.46) | BRD4MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7487239 | 0.82 | MAPT (0.46) | BRD4MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7551103 | 0.80 | MAPT (0.46) | BRD4MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7847494 | 0.80 | CCNT1 (0.40) | BRD4MAPTCCNT1CDK7CDK9 | |
| SCHEMBL7846049 | 0.80 | CCNT1 (0.39) | MAPTCCNT1CDK7CDK9CCNH | |
| SCHEMBL7835000 | 0.78 | MEN1 (0.43) | BRD4MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7003831 | 0.75 | MEN1 (0.45) | BRD4MAPTCCNT1CDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0714898-B1 | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2001-11-14 | — | — | EP | claimed |
| US-5707997-A | ANALGESICS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1998-01-13 | — | — | US | claimed |
| EP-0714898-A1 | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-06-05 | — | — | EP | claimed |
| JP-10101671-A | — | — | None | — | — | JP | disclosed |
| JP-8311068-A | — | — | None | — | — | JP | disclosed |
| EP-1404312-B1 | CARBAMATE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ORTHO MCNEIL PHARM INC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-19 | — | — | US | disclosed |
| EP-1404312-A1 | CARBAMATE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030092735-A1 | Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome | FARBER LOTHAR (DE) | 2003-05-15 | — | — | US | disclosed |
| WO-2002067922-A1 | CARBAMATE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| JP-2002053466-A | APOPTOSIS REGULATING AGENT | OTSUKA PHARMACEUT FACTORY INC | 2002-02-19 | — | — | JP | disclosed |
| EP-0714898-B1 | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2001-11-14 | — | — | EP | disclosed |
| EP-1107744-A2 | USE OF SUBSTANCE P ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME AND/OR FIBROMYALGIA AND USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME | Novartis AG (CH) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000010545-A2 | USE OF SUBSTANCE P ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME AND/OR FIBROMYALGIA AND USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME | NOVARTIS AG (CH) | 2000-03-02 | — | — | WO | disclosed |
| JP-H10101671-A | NITROGEN MONOXIDE SYNTHASE INHIBITOR | OTSUKA PHARMACEUT FACTORY INC | 1998-04-21 | — | — | JP | disclosed |
| US-5707997-A | ANALGESICS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1998-01-13 | — | — | US | disclosed |
| JP-H08311068-A | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUT FACTORY INC | 1996-11-26 | — | — | JP | disclosed |
| EP-0714898-A1 | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADORA2A, PDE4A, PDE4D | BRD4 183/4885MAPT 4717/4885CCNT1 342/4885 |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | BRD4 207/4885MAPT 4635/4885CCNT1 312/4885 |
| US-20030092735-A1 | Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome | TACR1, NPSR1, NPFFR1 | BRD4 3305/4885MAPT 4882/4885CCNT1 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.